Violet Therapeutics raised $4.8 million in a seed extension financing to advance its RABID-seq platform, which combines barcoded viral tracing with single-cell RNA sequencing to study interactions between brain cells. The company’s focus on neural circuitry mapping targets a core bottleneck in neuroscience drug discovery: assigning causal cellular interactions to observed phenotypes. A seed extension typically reflects progress toward proof points such as data quality, reproducibility, and early customer or internal validation use cases. The financing adds runway as the platform moves from enabling studies to broader application. For the market, Violet’s round signals ongoing investor appetite for neuroscience tools and computational/omics-driven platform companies, even as capital constraints persist for less-validated clinical-stage bets.